German Parkinson Study Group (GPS)
8
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
63%
5 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy
Role: lead
Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease
Role: lead
Study About Efficacy and Safety to Treat Multi-System-Atrophy
Role: lead
Double-blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia
Role: lead
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease
Role: collaborator
Multicenter Study on Fibrotic Valvular Heart Disease in Patients With Parkinson's Disease Treated With Dopamine Agonists
Role: lead
Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia
Role: lead
STN-Stimulation Versus Best Medical Treatment in Advanced PD
Role: lead
All 8 trials loaded